AUTHORS
Shaji Kumar, MD, Ashwini Kumar, PhD2, Saad Z. Usmani, MD3, Jing Christine Ye, M.D., MSc4, Maria-Victoria Mateos Jr, MD, PhD5, Joshua Richter I, MD6, Emma Scott7, Christoph Heuck8, Payal Thakkar9, Todd Henninger, PhD10, Cuc Davis, BS11, Onsay Lau12, Jaymala Patel, BS, MSc13, Stephanie Gaydos14, Paul Bojczuk15, Christopher Chiu16, Yael C. Cohen, MD17, Maria Krevvata18
AFFILIATIONS
1 Mayo Clinic Rochester, Rochester, United States
2 Johnson & Johnson, Spring House, United States
3 Memorial Sloan Kettering Cancer Center, New York, United States
4 MD Anderson Cancer Center, University of Texas, Houston, Houston, United States
5 University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Salamanca, Spain
6 The Tisch Cancer Institute, New York, United States
7 Johnson & Johnson, Spring House, United States
8 Johnson & Johnson, Raritan, United States
9 Johnson & Johnson, Raritan, United States
10 Johnson & Johnson - Cilag Unlimited UK, London, United Kingdom
11 Johnson & Johnson, Spring House, United States
12 Johnson & Johnson, Spring House, United States
13 Johnson & Johnson, Spring House, United States
14 Johnson & Johnson, Spring House, United States
15 Johnson & Johnson, Spring House, United States
16 Johnson & Johnson, Raritan, United States
17 Tel-Aviv Sourasky (Ichilov) Medical Center, Tel Aviv, Israel; Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel
18 Johnson & Johnson, Spring House, United States
ABSTRACT
Introduction: Patients with RRMM and EMD have poor outcomes and limited effective treatment options. Dual antigen targeting of BCMA and GPRC5D may deepen immune-mediated tumor killing and help overcome resistance to single-antigen T-cell–redirecting therapies. In the phase 1/2 RedirecTT-1 study, teclistamab (Tec; anti-BCMAxCD3 bispecific antibody) plus talquetamab (Tal; anti-GPRC5DxCD3 bispecific antibody) demonstrated high overall response rates and durable progression-free survival in patients with EMD. This dual-antigen strategy is now being evaluated in a phase 3 study in earlier-line RRMM across a broader population. Here, we present translational analyses from patients with EMD treated with the recommended phase 2 dose regimen of Tec + Tal to characterize baseline biomarkers, pharmacodynamic immune activation, and response-associated mechanisms.
Methods: Patients with RRMM and ≥1 measurable true EMD lesion (≥2 cm, non-contiguous with bone) and ECOG PS ≤2 were treated with Tec 3 mg/kg Q2W plus Tal 0.8 mg/kg SC Q2W. TR analyses were performed using longitudinal blood and baseline bone marrow samples; EMD tumor biopsies were not uniformly available due to feasibility. Responses were assessed by IMWG criteria including functional imaging for EMD response assessment. Serial peripheral blood samples were collected at baseline (prior to treatment), during step-up dosing, and cycle 1 day 1 (C1D1) through C7D1, while bone marrow aspirates were collected at baseline. Samples were analyzed by flow cytometry to assess BCMA and GPRC5D expression, immune cell populations, and cytokine profiling.
Results: Baseline bone marrow BCMA and GPRC5D expression levels and receptor densities were assessed in 18 patients and did not correlate with treatment response, suggesting that while target presence is required for dual-antigen engagement, baseline target abundance does not determine clinical outcome. Responders (n=66) demonstrated a more activated baseline bone marrow immune state, characterized by increased CD38 expression on CD8+ T cells than nonresponders (n=20), with concordant trends for HLA-DR+ CD8+ T cell + subsets. Tec + Tal induced pronounced peripheral T-cell redistribution followed by robust expansion. Although comparable peripheral T-cell redistribution patterns were observed across patients regardless of response, sustained T-cell expansion was restricted to responders, indicating distinct immune dynamics associated with clinical benefit. Tec + Tal also induced marked pharmacodynamic cytokine responses, with early elevations of IL-6, TNF-α, and IL-10 that were more pronounced in responders (n=69) than in nonresponders (n=19). These immune changes were accompanied by persistent expansion of activated CD38+CD8+ T cells, supporting a link between robust T-cell expansion/activation and therapeutic response in EMD.
Conclusions: BCMA and GPRC5D expression in bone marrow myeloma cells was not associated with clinical response of Tec + Tal in patients with RRMM and EMD. Instead, responders demonstrated enhanced baseline and treatment-induced immune activation, including earlier and greater cytokine induction, peripheral T-cell expansion, and sustained CD38+CD8+ T-cell activation, whereas nonresponders exhibited only transient T-cell redistribution. These findings identify immune activation signatures associated with clinical response to dual BCMA/GPRC5D targeting and support simultaneous multiantigen T-cell redirection as a strategy to overcome the biologic challenges of EMD.
DISCLOSURES
Shaji Kumar, MD: Allogene - Research Funding; Merck - Research Funding; Janssen Oncology - Research Funding; Gracell Bio - Research Funding; Telogenomics - Research Funding; Molecular Templates - Research Funding; Bristol Myers Squibb/Celgene - Research Funding; Novartis - Research Funding; Takeda - Research Funding; Astra Zeneca - Research Funding; Roche-Genentech - Research Funding; Roche - Research Funding; AstraZeneca - Research Funding; AbbVie - Research Funding; Bristol Myers Squibb - Research Funding; Amgen - Research Funding; KITE - Research Funding; Oricell - Research Funding; CARSgen Therapeutics - Research Funding; GSK - Research Funding; Adaptive - Research Funding; Celgene - Research Funding; Regeneron Pharmaceuticals, Inc. - Research Funding; Sanofi - Research Funding; Epizyme - Consultancy (Includes expert testimony); Seimens - Consultancy (Includes expert testimony); Monte Rosa Therapeutics - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Antengene - Consultancy (Includes expert testimony); Bristol Myers Squibb/Celgene - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); KITE - Consultancy (Includes expert testimony); GLH Pharma - Consultancy (Includes expert testimony); BeiGene - Consultancy (Includes expert testimony); Adaptive - Consultancy (Includes expert testimony); CVS Caremark - Consultancy (Includes expert testimony); Moderna - Consultancy (Includes expert testimony); bluebird bio - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Arcellx - Consultancy (Includes expert testimony); Trillium - Consultancy (Includes expert testimony); K36 - Consultancy (Includes expert testimony); Roche-Genentech - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Oncopeptides - Consultancy (Includes expert testimony); Secura Bio - Consultancy (Includes expert testimony); Regeneron Pharmaceuticals, Inc. - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Janssen Oncology - Consultancy (Includes expert testimony); Loxo Oncology - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); BD Biosciences - Consultancy (Includes expert testimony)